Magazine Article | December 1, 2021

What's The Outlook From Life Science Operations For 2022 — And Beyond?

Source: Life Science Leader

By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL

In 2015, when we published our first manufacturing outlook article, biologics accounted for less than 5% of total sales. Perhaps that’s why the article only included “Pharma Manufacturing” in its title. What a difference six years make, as biologics in at least four countries now constitute more than 30% of total pharmaceutical sales. But, with the average daily dose of a biologic costing roughly 22 times more than a small molecule, it seems that leaders in biopharmaceutical manufacturing have never faced a greater challenge. Here’s what 12 biopharma manufacturing execs have to say as they look to 2022 and beyond.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: